Acute Lung Injury - Pipeline Review, H2 2016

Date: December 30, 2016
Pages: 97
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until June 2, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AD39C797CC5EN
Leaflet:

Download PDF Leaflet

Acute Lung Injury - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lung Injury – Pipeline Review, H2 2016, provides an overview of the Acute Lung Injury (Respiratory) pipeline landscape.

Acute lung injury (ALI) is a common condition that is characterized by acute severe hypoxia that is not due to left atrial hypertension. ALI is most often seen as part of a systemic inflammatory process, particularly systemic sepsis, where the lung manifestations parallel those of other tissues. Causes of ALI include sepsis, burns, radiation, inhalation of noxious fumes and fat embolism. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lung Injury – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lung Injury (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lung Injury (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively.

Acute Lung Injury (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lung Injury (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Lung Injury (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lung Injury (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lung Injury (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lung Injury (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lung Injury (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lung Injury (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acute Lung Injury Overview
Therapeutics Development
Pipeline Products for Acute Lung Injury - Overview
Pipeline Products for Acute Lung Injury - Comparative Analysis
Acute Lung Injury - Therapeutics under Development by Companies
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes
Acute Lung Injury - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Lung Injury - Products under Development by Companies
Acute Lung Injury - Products under Investigation by Universities/Institutes
Acute Lung Injury - Companies Involved in Therapeutics Development
Altor BioScience Corp
Asklepion Pharmaceuticals LLC
Commence Bio Inc
CompleGen Inc
GlaxoSmithKline Plc
Histocell SL
Lung Therapeutics Inc
Navigen Pharmaceuticals Inc
Quark Pharmaceuticals Inc
S-Evans Biosciences Inc
Silence Therapeutics Plc
Stemedica Cell Technologies Inc
Acute Lung Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALT-836 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atu-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-1037 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAB-117HC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-Citrulline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LTI-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAV-2729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P- BEFizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPLI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-10001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins for Acute Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Lung Injury - Dormant Projects
Acute Lung Injury - Discontinued Products
Acute Lung Injury - Product Development Milestones
Featured News & Press Releases
Mar 03, 2015: Navigen Announces Phase I NIH SBIR Award to support the Development of ARF6 Inhibitors to Treat Acute Lung Injury/Acute Respiratory Distress
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Lung Injury, H2 2016
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Acute Lung Injury - Pipeline by Altor BioScience Corp, H2 2016
Acute Lung Injury - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016
Acute Lung Injury - Pipeline by Commence Bio Inc, H2 2016
Acute Lung Injury - Pipeline by CompleGen Inc, H2 2016
Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H2 2016
Acute Lung Injury - Pipeline by Histocell SL, H2 2016
Acute Lung Injury - Pipeline by Lung Therapeutics Inc, H2 2016
Acute Lung Injury - Pipeline by Navigen Pharmaceuticals Inc, H2 2016
Acute Lung Injury - Pipeline by Quark Pharmaceuticals Inc, H2 2016
Acute Lung Injury - Pipeline by S-Evans Biosciences Inc, H2 2016
Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H2 2016
Acute Lung Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Lung Injury - Dormant Projects, H2 2016
Acute Lung Injury - Dormant Projects (Contd..1), H2 2016
Acute Lung Injury - Dormant Projects (Contd..2), H2 2016
Acute Lung Injury - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Lung Injury, H2 2016
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Acute Lung Injury - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: